Page 324 - Read Online

Chen et al. Hepatoma Res 2018;4:29 I http://dx.doi.org/10.20517/2394-5079.2018.18 Page 15 of 15

117. Lima K, Krause G, Schuster A, Catarina A, Basso B, De Mesquita F, Pedrazza L, Marczak E, Martha B, Nunes F, Chiela E, Jaeger N,
Thomé M, Haute G, Dias H, Donadio M, De Oliveira J. Gallic acid reduces cell growth by induction of apoptosis and reduction of IL-8
in HepG2 cells. Biomed Pharmacother 2016;84:1282-90.
118. Sun G, Zhang S, Xie Y, Zhang Z, Zhao W. Gallic acid as a selective anticancer agent that induces apoptosis in SMMC-7721 human
hepatocellular carcinoma cells. Oncol Lett 2016;11:150-8.
119. Song M, Kim Y, Song M, Choi H, Park Y, Ryu J. Polycyclic aromatic hydrocarbons induce migration in human hepatocellular
carcinoma cells (HepG2) through reactive oxygen species-mediated p38 MAPK signal transduction. Cancer Sci 2011;102:1636-44.
120. Bie B, Sun J, Li J, Guo Y, Jiang W, Huang C, Yang J, Li Z. Baicalein, a natural anti-cancer compound, alters microRNA expression
profiles in Bel-7402 human hepatocellular carcinoma cells. Cell Physiol Biochem 2017;41:1519-31.
121. Gong W, Zhao Z, Liu B, Lu L, Dong J. Exploring the chemopreventive properties and perspectives of baicalin and its aglycone baicalein
in solid tumors. Eur J Med Chem 2017;126:844-52.
122. Igbe I, Shen X, Jiao W, Qiang Z, Deng T, Li S, Liu W, Liu H, Zhang G, Wang F. Dietary quercetin potentiates the antiproliferative effect
of interferon-α in hepatocellular carcinoma cells through activation of JAK/STAT pathway signaling by inhibition of SHP2 phosphatase.
Oncotarget 2017;8:113734-48.
123. Ren K, Li Y, Wu G, Ren J, Lu H, Li Z, Han X. Quercetin nanoparticles display antitumor activity via proliferation inhibition and
apoptosis induction in liver cancer cells. Int J Oncol 2017;50:1299-311.
124. Ma Y, Wang J, Liu L, Zhu H, Chen X, Pan S, Sun X, Jiang H. Genistein potentiates the effect of arsenic trioxide against human
hepatocellular carcinoma: role of Akt and nuclear factor-κB. Cancer Lett 2011;301:75-84.
125. Babu L, Perumal S, Balasubramanian M. Myrtenal, a natural monoterpene, down-regulates TNF-α expression and suppresses
carcinogen-induced hepatocellular carcinoma in rats. Mol Cell Biochem 2012;369:183-93.
126. Zaghloul R, Elsherbiny N, Kenawy H, El-Karef A, Eissa L, El-Shishtawy M. Hepatoprotective effect of hesperidin in hepatocellular
carcinoma: involvement of Wnt signaling pathways. Life Sci 2017;185:114-25.
127. Lin X, Kong L, Huang C, Ma T, Meng X, He Y, Wang Q, Li J. Hesperetin derivative-7 inhibits PDGF-BB-induced hepatic stellate cell
activation and proliferation by targeting Wnt/β-catenin pathway. Int Immunopharmacol 2015;25:311-20.
128. Zhang J, Song J, Wu D, Wang J, Dong W. Hesperetin induces the apoptosis of hepatocellular carcinoma cells via mitochondrial pathway
mediated by the increased intracellular reactive oxygen species, ATP and calcium. Med Oncol 2015;32:101.
129. Lee K, Yeh M, Kao S, Hung C, Liu C, Huang Y, Yeh C. The inhibitory effect of hesperidin on tumor cell invasiveness occurs via
suppression of activator protein 1 and nuclear factor-kappaB in human hepatocellular carcinoma cells. Toxicol Lett 2010;194:42-9.
130. Xu X, Zhang K, Zhao L, Li C, Bu W, Shen Y, Gu Z, Chang B, Zheng C, Lin C, Sun H, Yang B. Aspirin-based carbon dots, a good
biocompatibility of material applied for bioimaging and anti-inflammation. ACS Appl Mater Interfaces 2016;8:32706-16.
131. Abdelmonsif D, Sultan A, El-Hadidy W, Abdallah D. Targeting AMPK, mTOR and β-catenin by combined metformin and aspirin
therapy in HCC: an appraisal in Egyptian HCC patients. Mol Diagn Ther 2018;22:115-27.
132. Xia H, Hui KM. Emergence of aspirin as a promising chemopreventive and chemotherapeutic agent for liver cancer. Cell Death Dis
2017;8:e3112.
133. Márquez-Rosado L, Trejo-Solís M, García-Cuéllar C, Villa-Treviño S. Celecoxib, a cyclooxygenase-2 inhibitor, prevents induction of
liver preneoplastic lesions in rats. J Hepatol 2005;43:653-60.
134. Behari J, Zeng G, Otruba W, Thompson M, Muller P, Micsenyi A, Sekhon S, Leoni L, Monga S. R-Etodolac decreases beta-catenin
levels along with survival and proliferation of hepatoma cells. J Hepatol 2007;46:849-57.
135. Nagahara T, Okano J, Fujise Y, Abe R, Murawaki Y. Preventive effect of JTE-522, a selective cyclooxygenase-2 inhibitor, on DEN-
induced hepatocarcinogenesis in rats. Biomed Pharmacother 2010;64:319-26.
136. Yin G, Tu K, Han S, Wang J, Liu Q, Yao Y. Downregulation of HSP70 gene expression and apoptosis in human hepatocellular
carcinoma SMMC-7721 cells induced by nimesulide in vitro. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi 2012;28:933-6. (in Chinese)
137. Pei Q, Jiang P, Yang M, Qian X, Liu J, Kim S. Roxithromycin inhibits VEGF-induced human airway smooth muscle cell proliferation:
Opportunities for the treatment of asthma. Exp Cell Res 2016;347:378-84.
138. Ding D, Huang H, Jiang W, Yu W, Zhu H, Liu J, Saiyin H, Wu J, Huang H, Jiang S, Yu L. Reticulocalbin-2 enhances hepatocellular
carcinoma proliferation via modulating the EGFR-ERK pathway. Oncogene 2017;36:6691-700.
139. Chen L, Zhou D, Liu Z, Huang X, Liu Q, Kang Y, Chen Z, Guo Y, Zhu H, Sun C. Combination of gemcitabine and erlotinib inhibits
recurrent pancreatic cancer growth in mice via the JAK-STAT pathway. Oncol Rep 2018;39:1081-9.
140. Kaseb A, Morris J, Iwasaki M, Al-Shamsi H, Raghav K, Girard L, Cheung S, Nguyen V, Elsayes K, Xiao L, Abdel-Wahab R, Shalaby A,
Hassan M, Hassabo H, Wolff R, Yao J. Phase II trial of bevacizumab and erlotinib as a second-line therapy for advanced hepatocellular
carcinoma. Onco Targets Ther 2016;9:773-80.
141. Finn R. Emerging targeted strategies in advanced hepatocellular carcinoma. Semin Liver Dis 2013;33 Suppl 1:S11-9.
142. Wu Z, Galmiche A, Liu J, Stadler N, Wendum D, Segal-Bendirdjian E, Paradis V, Forgez P. Neurotensin regulation induces
overexpression and activation of EGFR in HCC and restores response to erlotinib and sorafenib. Cancer Lett 2017;388:73-84.
143. Villanueva A, Luedde T. The transition from inflammation to cancer in the liver. Clinical Liver Disease 2016;8:89-93.
144. El-Khoueiry AB, Sangro B, Yau T, Crocenzi TS, Kudo M, Hsu C, Kim TY, Choo SP, Trojan J, Welling 3rd TH. Nivolumab in patients
with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion
trial. Lancet 2017;389:2492-502.